Adrian J. Haigh Sells 22,223 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh sold 22,223 shares of the stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of C$9.32, for a total value of C$207,029.47.

Adrian J. Haigh also recently made the following trade(s):

• On Monday, April 15th, Adrian J. Haigh acquired 22,222 shares of Fennec Pharmaceuticals stock. The stock was bought at an average price of C$2.31 per share, for a total transaction of C$51,332.82.

Fennec Pharmaceuticals Stock Performance

TSE FRX opened at C$12.80 on Thursday. The stock has a market cap of C$346.11 million, a PE ratio of -12.55 and a beta of 0.35. The company has a debt-to-equity ratio of 881.09, a quick ratio of 10.17 and a current ratio of 3.29. The firm has a 50-day moving average of C$13.50 and a 200-day moving average of C$12.74. Fennec Pharmaceuticals Inc. has a 52-week low of C$9.27 and a 52-week high of C$15.43.

Fennec Pharmaceuticals (TSE:FRX) last released its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) earnings per share for the quarter, missing the consensus estimate of C$0.02 by C($0.16). Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative return on equity of 1,005.59%. The company had revenue of C$13.25 million during the quarter, compared to the consensus estimate of C$12.88 million. On average, sell-side analysts anticipate that Fennec Pharmaceuticals Inc. will post 0.4202312 EPS for the current year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.